These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32926241)

  • 1. Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
    Lechner K; Kessler T; Schunkert H
    Curr Cardiol Rep; 2020 Sep; 22(11):146. PubMed ID: 32926241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?
    Hadley TD; Agha AM; Ballantyne CM
    Curr Atheroscler Rep; 2021 Apr; 23(6):28. PubMed ID: 33791884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator.
    Khera A; Budoff MJ; O'Donnell CJ; Ayers CA; Locke J; de Lemos JA; Massaro JM; McClelland RL; Taylor A; Levine BD
    Circulation; 2018 Oct; 138(17):1819-1827. PubMed ID: 30354651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction.
    Nurmohamed NS; Kraaijenhof JM; Mayr M; Nicholls SJ; Koenig W; Catapano AL; Stroes ESG
    Eur Heart J; 2023 May; 44(18):1594-1607. PubMed ID: 36988179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA.
    Mortensen MB; Falk E; Li D; Nasir K; Blaha MJ; Sandfort V; Rodriguez CJ; Ouyang P; Budoff M
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 1):221-230. PubMed ID: 28624395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition.
    Rosenblit PD
    Curr Diab Rep; 2019 Jul; 19(8):61. PubMed ID: 31332544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Risk Assessment for Atherosclerotic Cardiovascular Disease: A Guide for the General Cardiologist.
    Belanger MJ; Kelly EM; Tahir UA; Benson MD
    Cardiol Rev; 2022 Jul-Aug 01; 30(4):206-213. PubMed ID: 33758125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications.
    Aragam KG; Natarajan P
    Circ Res; 2020 Apr; 126(9):1159-1177. PubMed ID: 32324503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.
    Sanin V; Pfetsch V; Koenig W
    Curr Cardiol Rep; 2017 Jul; 19(7):61. PubMed ID: 28528455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy.
    Miname MH; Bittencourt MS; Moraes SR; Alves RIM; Silva PRS; Jannes CE; Pereira AC; Krieger JE; Nasir K; Santos RD
    JACC Cardiovasc Imaging; 2019 Sep; 12(9):1797-1804. PubMed ID: 30448145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin therapy for young adults: A long-term investment worth considering.
    Miedema MD; Nauffal VD; Singh A; Blankstein R
    Trends Cardiovasc Med; 2020 Jan; 30(1):48-53. PubMed ID: 30808553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
    Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
    Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation and Cardiovascular Disease: The Future.
    Arnold N; Lechner K; Waldeyer C; Shapiro MD; Koenig W
    Eur Cardiol; 2021 Feb; 16():e20. PubMed ID: 34093741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years.
    Duncan MS; Vasan RS; Xanthakis V
    J Am Heart Assoc; 2019 Jun; 8(11):e011433. PubMed ID: 31137992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment].
    Arai H
    Rinsho Byori; 2014 Sep; 62(9):878-83. PubMed ID: 27526533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.